Transfer pricing lessons from South Africa's Tax Court Case No IT 14302
Inside the landmark SARS vs ABD Limited judgment: how a 1% royalty rate survived a 3% assessment, and what it means for multinationals in Africa.
When the South African Revenue Service challenged the 1% royalty rate a South African telecommunications group charged fourteen of its operating companies for the use of its intellectual property, it issued an assessment tripling the rate to 3%. This analysis walks through what happened next: the Tax Court ruled in favour of ABD Limited, set aside SARS's assessment, and accepted an internal comparable uncontrolled price from a Cyprus agreement as proof that the 1% rate was at arm's length under section 31 of the Income Tax Act.
The judgment sets a precedent in a seldom-litigated field of tax law. For revenue services across Africa, it underscores that transfer pricing assessments must rest on solid evidence and clear justification before deviating from established expert opinion. For multinationals, it illustrates the complexities and financial stakes of transfer pricing litigation, and why intercompany transactions must be demonstrably at arm's length.
The analysis also examines the role of specialist representation in the outcome. Prof. Dr. Daniel N. Erasmus and his team, whose expert analysis and testimony supported ABD Limited's defence, have settled transfer pricing cases for an average of 3% of the original assessments, upwards of US$5 billion in total, and bring particular depth in valuing intangible assets, business restructurings, and data-driven transfer pricing models in the post-BEPS landscape.
The closing chapters turn the case into practice: how to manage transfer pricing risk through a Tax Steering Committee, from composition, governance and client-attorney privilege to initial risk audits, training, and continuous improvement, whether you are establishing a committee for the first time or strengthening one that already exists.
“The Tax Court ruled in favor of ABD Limited, setting aside SARS's assessment.”Prof. Dr. Daniel N. Erasmus